Suppression of centrosome amplification after DNA damage depends on p27 accumulation

Cancer Research

Volumn 66, Issue 8, 2006, Pages 4020-4029

  Sugihara, Eiji ^a,b   Kanai, Masayuki ^c   Saito, Soichiro ^a,b   Nitta, Takayuki ^a,b   Toyoshima, Hideo ^b   Nakayama, Keiko ^d   Nakayama, Keiichi I ^e   Fukasawa, Kenji ^c   Schwab, Manfred ^f   Saya, Hideyuki ^g   Miwa, Masanao ^a,b  

^a NAGAHAMA INSTITUTE OF BIO SCIENCE AND TECHNOLOGY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d TOHOKU UNIVERSITY   (Japan)

^e KYUSHU UNIVERSITY   (Japan)

^f GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^g KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; F BOX PROTEIN; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; SMALL INTERFERING RNA; UBIQUITIN PROTEIN LIGASE;

ANIMAL CELL; ARTICLE; CENTROSOME; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; EMBRYO; FIBROBLAST; GAMMA IRRADIATION; HUMAN; HUMAN CELL; MALE; MITOSIS; NONHUMAN; ONCOGENE; ONCOGENE MYCN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CENTROSOME; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DNA DAMAGE; DNA-BINDING PROTEINS; DOWN-REGULATION; GAMMA RAYS; HUMANS; MITOSIS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; S-PHASE KINASE-ASSOCIATED PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 33646265046     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3250     Document Type: Article

References (50)

1. Fukasawa K. Centrosome: introduction. Oncogene 2002;21:6140-5.
2. Meraldi P, Nigg EA. The centrosome cycle. FEBS Lett 2002;521:9-13.
3. Lingle WL, Lutz WH, Ingle JN, Maihle NJ, Salisbury JL. Centrosome hypertrophy in human breast tumors: implications for genomic stability and cell polarity. Proc Natl Acad Sci U S A 1998;95:2950-5.
4. Pihan GA, Purohit A, Wallace J, et al. Centrosome defects and genetic instability in malignant tumors. Cancer Res 1998;58:3974-85.
5. Carroll PE, Okuda M, Horn HF, et al. Centrosome hyperamplification in human cancer: chromosome instability induced by p53 mutation and/or Mdm2 overexpression. Oncogene 1999;18:1935-44.
6. Sato N, Mizumoto K, Nakamura M, et al. Centrosome abnormalities in pancreatic ductal carcinoma. Clin Cancer Res 1999;5:963-70.
7. Fukasawa K, Choi T, Kuriyama R, Rulong S, Vande Woude GF. Abnormal centrosome amplification in the absence of p53. Science 1996;271:1744-7.
8. Xu ZX, Zou WX, Lin P, Chang KS. A role for PML3 in centrosome duplication and genome stability. Mol Cell 2005;17:721-32.
9. Hinchcliffe EH, Li C, Thompson EA, Maller JL, Sluder G. Requirement of Cdk2-cyclin E activity for repeated centrosome reproduction in Xenopus egg extracts:. Science 1999;283:851-4.
10. Meraldi P, Lukas J, Fry AM, Bartek J, Nigg EA. Centrosome duplication in mammalian somatic cells requires E2F and Cdk2-cyclin A. Nat Cell Biol 1999;1:88-93.
11. Okuda M, Horn HF, Tarapore P, et al. Nucleophosmin/B23 is a target of CDK2/cyclin E in centrosome duplication. Cell 2000;103:127-40.
12. Fisk HA, Winey M. The mouse Mps1p-like kinase regulates centrosome duplication. Cell 2001;106:95-104.
13. Chen Z, Indjeian VB, McManus M, Wang L, Dynlacht BD. CP110, a cell cycle-dependent CDK substrate, regulates centrosome duplication in human cells. Dev Cell 2002;3:339-50.
14. Matsumoto Y, Hayashi K, Nishida E. Cyclin-dependent kinase 2 (Cdk2) is required for centrosome duplication in mammalian cells. Curr Biol 1999;9:429-32.
15. Polyak K, Lee MH, Erdjument-Bromage H, et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994;78:59-66.
16. 1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994;78:67-74.
17. Hengst L, Dulic V, Slingerland JM, Lees E, Reed SI. A cell cycle-regulated inhibitor of cyclin-dependent kinases. Proc Natl Acad Sci U S A 1994;91:5291-5.
18. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003;13:41-7.
19. Sutterluty H, Chatelain E, Marti A, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol 1999;1:207-14.
20. Carrano AC, Eytan E, Hershko A, Pagano M. SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol 1999;1:193-9.
21. 1 phase. Nat Cell Biol 2004;6:1229-35.
22. Motoyama N, Naka K. DNA damage tumor suppressor genes and genomic instability. Curr Opin Genet Dev 2004;14:11-6.
23. 2 arrest after DNA damage. Science 1998;282:1497-501.
24. 1/S cell cycle checkpoint. Oncogene 2004;23:4068-75.
25. Yoon HS, Ghaleb AM, Nandan MO, Hisamuddin IM, Dalton WB, Yang VW. Kruppel-like factor 4 prevents centrosome amplification following gamma-irradiation-induced DNA damage. Oncogene 2005;24:4017-25.
26. 2 phase and involves ATM. EMBO J 2004;23:3864-73.
27. Sugihara E, Kanai M, Matsui A, Onodera M, Schwab M, Miwa M. Enhanced expression of MYCN leads to centrosome hyperamplification after DNA damage in neuroblastoma cells. Oncogene 2004;23:1005-9.
28. Schwab M. MYCN in neuronal tumours. Cancer Lett 2004;204:179-87.
29. Nakayama K, Ishida N, Shirane M, et al. Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996;85:707-20.
30. Tarapore P, Horn HF, Tokuyama Y, Fukasawa K. Direct regulation of the centrosome duplication cycle by the p53-21Waf1/Cip1 pathway. Oncogene 2001;20:3173-84.
31. Marumoto T, Honda S, Hara T, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278:51786-95.
32. 1 arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol 2001;158:2067-77.
33. Hashimoto Y, Kohri K, Kaneko Y, et al. Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression. J Biol Chem 1998;273:16544-50.
34. Sato N, Mizumoto K, Nakamura M, et al. A possible role for centrosome overduplication in radiation-induced cell death. Oncogene 2000;19:5281-90.
35. Kawamura K, Fujikawa-Yamamoto K, Ozaki M, et al. Centrosome hyperamplification and chromosomal damage after exposure to radiation. Oncology 2004;67:460-70.
36. Imaki H, Nakayama K, Delehouzee S, et al. Cell cycle-dependent regulation of the Skp2 promoter by GA-binding protein. Cancer Res 2003;63:4607-13.
37. Bashir T, Dorrello NV, Amador V, Guardavaccaro D, Pagano M. Control of the SCF(Skp2-1) ubiquitin ligase by the APC/C(Cdh1) ubiquitin ligase. Nature 2004;428:190-3.
38. 1 by the anaphase-promoting complex. Nature 2004;428:194-8.
39. kip1. Nature 2000;404:782-7.
40. Jiang F, Caraway NP, Li R, Katz RL. RNA silencing of S-phase kinase-interacting protein 2 inhibits proliferation and centrosome amplification in lung cancer cells. Oncogene 2005;24:3409-18.
41. Ortega S, Prieto I, Odajima J, et al. Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003;35:25-31.
42. Berthet C, Aleem E, Coppola V, Tessarollo L, Kaldis P. Cdk2 knockout mice are viable. Curr Biol 2003;13:1775-85.
43. Martin A, Odajima J, Hunt SL, et al. Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005;7:591-8.
44. 1/S phase transition. Nat Cell Biol 2005;7:831-6.
45. Duensing S, Duensing A, Lee DC, et al. Cyclin-dependent kinase inhibitor indirubin-3′-oxime selectively inhibits human papillomavirus type 16 E7-induced numerical centrosome anomalies. Oncogene 2004;23:8206-15.
46. Nakayama K, Nagahama H, Minamishima YA, et al. Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication. EMBO J 2000;19:2069-81.
47. Nakayama K, Nagahama H, Minamishima YA, et al. Skp2-mediated degradation of p27 regulates progression into mitosis. Dev Cell 2004;6:661-72.
48. Fero ML, Randel E, Gurley KE, Roberts JM, Kemp CJ. The murine gene p27Kip1 is haplo-insufficient for tumour suppression. Nature 1998;396:177-80.
49. Gstaiger M, Jordan R, Lim M, et al. Skp2 is oncogenic and overexpressed in human cancers. Proc Natl Acad Sci U S A 2001;98:5043-8.
50. Nakamura M, Matsuo T, Stauffer J, Neckers L, Thiele CJ. Retinoic acid decreases targeting of p27 for degradation via an N-myc-dependent decrease in p27 phosphorylation and an N-myc-independent decrease in Skp2. Cell Death Differ 2003;10:230-9.